Bind picks a new CEO; Neos swings for $69M in IPO;

@FierceBiotech: FierceBiotech Radio on GlaxoSmithKline rumors, Allergan's new identity and Axovant's IPO. Listen | Follow @FierceBiotech

@JohnCFierce: Anthem going after Cigna -- payer consolidation will increase pressure on U.S. drug pricing. NYT story | Follow @JohnCFierce

@DamianFierce: True Detective is terrible and I'm going to watch the whole season. I don't deserve to vote. | Follow @DamianFierce

> Bind Therapeutics ($BIND) has removed "interim" from CEO Andrew Hirsch's title, appointing the former CFO to fill the outgoing Scott Minick's role permanently. More

> China's 3SBio, which pulled off a $711 million IPO this month, acquired the global rights to a TNF blocker it believes can outclass the blockbusters Enbrel and Humira. News

> Texas biotech Neos Therapeutics is lining up for a $69 million IPO, hoping to fund its development of reformulated treatments for ADHD. Filing

Medical Device News

@FierceMedDev: ICYMI from FierceDrugDelivery: Teva partners with Microchips Biotech to deliver drugs via wirelessly controlled implant. Article | Follow @FierceMedDev

@VarunSaxena2: FDA approves novel tongue sensor for the blind. ICYMI Friday | Follow @VarunSaxena2

@EmilyWFierce: Loaded up with debt from M&A binge, Valeant still needs more deals. More from FiercePharma | Follow @EmilyWFierce

> Foundation Medicine teams up with IMS Health for cancer precision medicine project. More

> Report: TAVR procedures seen to change cardiac care in the U.S. Story

Pharma News

@FiercePharma: ICYMI Friday: Biosimilar of Novartis' eye drug Lucentis launched in India. Report | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. FiercePharmaManufacturing feature | Follow @EricPFierce

@CarlyHFierce: ICYMI: Teva turns up the heat on Mylan, taking its stake past critical threshold. Article | Follow @CarlyHFierce

> Which Big Biotechs join Gilead in Fortune's fastest-growing pharma ranks? Article

> Loaded up with debt from M&A binge, Valeant still needs more deals. Story

> Adults are now the prime market for ADHD drugs in U.S. More

Animal Health News

> Patterson closes on $1.1B deal for Animal Health International, doubling size of its vet unit. News

> Startup Rex clears $1M, starts hiring in KC Animal Health Corridor. More

> Zoetis to cut 165 workers from NJ headquarters as downsizing gets underway. Story

> Report: DNA-based injections to fuel growth of animal vaccines market. Item

> Vets and pharma execs gather in DC to trade notes on pets in cancer research. Article

Biotech IT News

> Pfizer's Lipset plots path to mainstream acceptance of experimental trial techs. News

> DIA starts with a flurry of hires, deals and product updates. Report

> GSK gives Altius $95M and a mission to hire computer scientists for 'living genome' research. More

> REMS website overhauled by FDA to simplify access to information. Story

> FDA digs into PatientsLikeMe's data to add patients' voices to safety monitoring. Article

Pharma Marketing News

> Social listening should be a no-brainer for pharma, study finds. Report

> It's Teva vs. Momenta/Sandoz for Copaxone patients, with Mylan's version MIA. Item

> AstraZeneca nabs top pharma ad award at Cannes amid slim product-specific field. Article

> Can Allergan make double-chin drug pay off? Maybe, but slowly, analysts say. More

> Pharma ad budgets to dip in 2016, but J&J, Pfizer, Roche and Novartis should still top $2B. Story

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.